top of page
Grandmother affectionately kissing her grandchild, representing family care and well-being.

Bacterial intelligence engineered to deliver unprecedented solutions in medicine

Smiling older couple consulting with a doctor, emphasizing patient care and trust in healthcare.

Our Mission

Our mission is to harness the biological intelligence of bacteria, further engineered by Actym, to create biologically brilliant therapeutics that provide an unprecedented level of impact in the treatment of cancer and fibrotic disease.  

Our mission is to harness the biological intelligence of bacteria, further engineered by Actym, to create biologically brilliant therapeutics that provide an unprecedented level of impact in the treatment of cancer and fibrotic disease.  

Smiling older couple consulting with a doctor, emphasizing patient care and trust in healthcare.
Close-up of bacterial cells, illustrating advanced biotechnology and cellular structures.

Our STACT™ (S. Typhimurium Anti-Cancer Therapy) platform is a precisely engineered bacterial delivery vehicle that is designed to be safely systemically administered and deliver multiple therapeutic payloads that are amplified and produced locally at the disease site, thereby avoiding therapeutic limiting systemic toxicity experienced when the payloads have been administered by other means.

Close-up of bacterial cells, illustrating advanced biotechnology and cellular structures.

Our STACT™ (S. Typhimurium Anti-Cancer Therapy) platform is a precisely engineered bacterial delivery vehicle that is designed to be safely systemically administered and deliver multiple therapeutic payloads that are amplified and produced locally at the disease site, thereby avoiding therapeutic limiting systemic toxicity experienced when the payloads have been administered by other means.

Our Science

Woman embracing her mother in a bright kitchen, symbolizing support and family connection.

Our Clinical Trial

Actym is currently evaluating ACTM-838 in a phase 1a/1b clinical trial in patients with advanced solid tumors.

Actym is currently evaluating ACTM-838 in a phase 1a/1b clinical trial in patients with advanced solid tumors.

Woman embracing her mother in a bright kitchen, symbolizing support and family connection.

News and Events

June 25, 2024

Actym Therapeutics Expands Management Team with Key Appointments to Build Product Pipeline and Advance Clinical Development Strategies

May 30, 2024

Actym Therapeutics Announces IND Clearance for Phase 1 Clinical Trial Investigating Lead Program ACTM-838 in Patients with Solid Tumors

actym footer final.jpg
bottom of page